22-15 PLAN

About this trial

Plasma genotyping, or ‘liquid biopsy,’ is a relatively new technology in which circulating tumour DNA (ctDNA) shed into the bloodstream by tumours, is detectable by NGS. Currently in Ireland, liquid biopsy technology is used solely to diagnose mechanisms of resistance to targeted therapy in EGFR-mutant NSCLC, and not as an initial diagnostic test.

To support the specific aims of the proposal, Study team aims to develop an ethics-approved prospective protocol to identify patients with advanced NSCLC suitable for genomic testing. In patients with newly diagnosed advanced or locally advanced non-squamous NSCLC at initial diagnostic evaluation identified at standard weekly lung MDTs seen in the Rapid Access Lung Clinic, patients will be offered a research plasma genotyping test, alongside standard tissue genotyping.

Patient Profile

  • Patient age >= 18 years
  • Histologically-proved non-squamous NSCLC
  • Willingness to provide informed consent.
  • ECOG PS 0-2

Where’s this trial being run?

Beaumont Hospital, St James’s Hospital, and University Hospital Limerick

Can I join this study / trial?

The first thing you do is to talk to your doctor and/or the cancer trials research team in your hospital. The contact details for the cancer trials research units in Ireland is here.

Why not Print this page and bring it with you. It will help your doctor and research team advise you.

For more detailed information


Here’s a list of questions you may have for your doctor or local cancer research team.

Summary Data

Name: 22-15 PLAN
Number: 22-15
Full Title:

PLAsma genomic testing in Patients with Advanced Non-Small Cell Lung Cancer

Principal Investigator: Dr Greg Korpanty and Dr David O'Reilly
Type: In-House


Recruitment Started: Global:
Global Recruitment Target:
Ireland Recruitment Target: 100